GlassScriptPhysician profile
Kent C Keys
NPI 1760572960
$5,969.35
in general payments reported to CMS, 2019-2025
28 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $455 · 2021: $1,320 · 2022: $933 · 2023: $843 · 2024: $426 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.40 | 2022-2025 | |
| Allergan, INC. | $637.09 | 2019-2022 | |
| Alcon Vision LLC | $610.35 | 2019-2025 | Hydrus Microstent, Tryptyr, Simbrinza |
| Eyevance Pharmaceuticals LLC | $583.83 | 2019-2023 | Tobradex St |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $461.88 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $287.15 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $281.49 | 2019-2021 | |
| Sight Sciences, INC. | $278.54 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Mallinckrodt Hospital Products INC. | $249.07 | 2021-2023 | Acthar |
| Bausch & Lomb Americas INC. | $203.32 | 2022-2025 | Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $179.61 | 2019-2023 | |
| Iridex Corporation | $166.05 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $160.61 | 2019-2025 | Cequa |
| Glaukos Corporation | $127.80 | 2019-2021 | |
| Oyster Point Pharma, INC. | $125.20 | 2022-2024 | Tyrvaya, Ryzumvi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $122.86 | 2024 | |
| Harrow Eye, LLC | $119.84 | 2025 | Vevye |
| Dompe US, INC. | $82.43 | 2022-2025 | Oxervate |
| Alexion Pharmaceuticals, INC. | $67.48 | 2022-2024 | Ultomiris |
| Tarsus Pharmaceuticals, INC. | $56.83 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $31.17 | 2021 | |
| Rxsight INC | $28.09 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Akorn, INC. | $24.37 | 2020 | |
| Biotissue Holdings INC. | $24.18 | 2022 | |
| Astellas Pharma US INC | $19.92 | 2024 | Izervay |
| Mallinckrodt Enterprises LLC | $19.00 | 2019 | |
| Maculogix, INC. | $12.38 | 2019 | |
| Eyepoint US, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.